177 related articles for article (PubMed ID: 29929861)
1. Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trials.
von den Grün JM; Hartmann A; Fietkau R; Ghadimi M; Liersch T; Hohenberger W; Weitz J; Sauer R; Wittekind C; Ströbel P; Rödel C; Fokas E;
Radiother Oncol; 2018 Sep; 128(3):557-563. PubMed ID: 29929861
[TBL] [Abstract][Full Text] [Related]
2. Stage-Dependent Frequency of Lymph Node Metastases in Patients With Rectal Carcinoma After Preoperative Chemoradiation: Results from the CAO/ARO/AIO-94 Trial and From a Comparative Prospective Evaluation With Extensive Pathological Workup.
Sprenger T; Rothe H; Conradi LC; Beissbarth T; Kauffels A; Kitz J; Homayounfar K; Wolff H; Ströbel P; Ghadimi M; Wittekind C; Sauer R; Rödel C; Liersch T
Dis Colon Rectum; 2016 May; 59(5):377-85. PubMed ID: 27050599
[TBL] [Abstract][Full Text] [Related]
3. [Lymph node metastases in ypT1/2 rectal cancer after neoadjuvant chemoradiotherapy : The Achilles heel of organ-preserving operative procedures?].
Sprenger T; Rothe H; Beissbarth T; Conradi LC; Kauffels A; Homayounfar K; Behnes CL; Rödel C; Liersch T; Ghadimi M
Chirurg; 2016 Jul; 87(7):593-601. PubMed ID: 27106241
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological characteristics predict lymph node metastases in ypT0-2 rectal cancer after chemoradiotherapy.
Bosch SL; Vermeer TA; West NP; Swellengrebel HA; Marijnen CA; Cats A; Verhoef C; van Lijnschoten I; de Wilt JH; Rutten HJ; Nagtegaal ID
Histopathology; 2016 Nov; 69(5):839-848. PubMed ID: 27270756
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy.
Park IJ; You YN; Skibber JM; Rodriguez-Bigas MA; Feig B; Nguyen S; Hu CY; Chang GJ
Dis Colon Rectum; 2013 Feb; 56(2):135-41. PubMed ID: 23303140
[TBL] [Abstract][Full Text] [Related]
6. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial.
Fokas E; Liersch T; Fietkau R; Hohenberger W; Beissbarth T; Hess C; Becker H; Ghadimi M; Mrak K; Merkel S; Raab HR; Sauer R; Wittekind C; Rödel C
J Clin Oncol; 2014 May; 32(15):1554-62. PubMed ID: 24752056
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
8. Lymph node metastases in rectal cancer after preoperative radiochemotherapy: impact of intramesorectal distribution and residual micrometastatic involvement.
Sprenger T; Rothe H; Becker H; Beissbarth T; Homayounfar K; Gauss K; Kitz J; Wolff H; Scheel AH; Ghadimi M; Rödel C; Conradi LC; Liersch T
Am J Surg Pathol; 2013 Aug; 37(8):1283-9. PubMed ID: 23851331
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized phase II/III trials.
Diefenhardt M; Fleischmann M; Martin D; Hofheinz RD; Piso P; Germer CT; Hambsch P; Grützmann R; Kirste S; Schlenska-Lange A; Ghadimi M; Rödel C; Fokas E;
Radiother Oncol; 2023 Feb; 179():109455. PubMed ID: 36572280
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological factors predict residual lymph node metastasis in locally advanced rectal cancer with ypT0-2 after neoadjuvant chemoradiotherapy.
Cui Y; Song M; Tie J; Li S; Wang H; Zhang Y; Geng J; Liu Z; Teng H; Sui X; Zhu X; Cai Y; Li Y; Wang W
J Cancer Res Clin Oncol; 2024 Apr; 150(4):176. PubMed ID: 38575793
[TBL] [Abstract][Full Text] [Related]
11. Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer: Secondary Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
Kitz J; Fokas E; Beissbarth T; Ströbel P; Wittekind C; Hartmann A; Rüschoff J; Papadopoulos T; Rösler E; Ortloff-Kittredge P; Kania U; Schlitt H; Link KH; Bechstein W; Raab HR; Staib L; Germer CT; Liersch T; Sauer R; Rödel C; Ghadimi M; Hohenberger W;
JAMA Surg; 2018 Aug; 153(8):e181607. PubMed ID: 29874375
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcome of Rectal Cancer With Clinically (EUS/MRI) Metastatic Mesorectal Lymph Nodes Treated by Neoadjuvant Chemoradiation: Role of Organ Preservation Strategies in Relation to Pathologic Response.
Belluco C; Forlin M; Olivieri M; Cannizzaro R; Canzonieri V; Buonadonna A; Bidoli E; Matrone F; Bertola G; De Paoli A
Ann Surg Oncol; 2016 Dec; 23(13):4302-4309. PubMed ID: 27489059
[TBL] [Abstract][Full Text] [Related]
13. [Risk factors related to lymph node metastases after neoadjuvant therapy for locally advanced rectal cancer].
Zeng ZF; Ding PR; Pan ZZ; Lin JZ; Li LR; Lu ZH; Wu XJ; Kong LH; Zhou ZG; Wan DS
Ai Zheng; 2009 Sep; 28(9):923-7. PubMed ID: 19728908
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of pathological node status after neoadjuvant radiotherapy for rectal cancer.
Duchalais E; Glyn Mullaney T; Spears GM; Kelley SR; Mathis K; Harmsen WS; Larson DW
Br J Surg; 2018 Oct; 105(11):1501-1509. PubMed ID: 29663352
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial.
Fokas E; Fietkau R; Hartmann A; Hohenberger W; Grützmann R; Ghadimi M; Liersch T; Ströbel P; Grabenbauer GG; Graeven U; Hofheinz RD; Köhne CH; Wittekind C; Sauer R; Kaufmann M; Hothorn T; Rödel C;
Ann Oncol; 2018 Jul; 29(7):1521-1527. PubMed ID: 29718095
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of nodal involvement in rectal cancer after chemoradiotherapy.
Haak HE; Beets GL; Peeters K; Nelemans PJ; Valentini V; Rödel C; Kuo L; Calvo FA; Garcia-Aguilar J; Glynne-Jones R; Pucciarelli S; Suarez J; Theodoropoulos G; Biondo S; Lambregts DMJ; Beets-Tan RGH; Maas M
Br J Surg; 2021 Oct; 108(10):1251-1258. PubMed ID: 34240110
[TBL] [Abstract][Full Text] [Related]
17. Oncologic Safety of Local Excision Compared With Total Mesorectal Excision for ypT0-T1 Rectal Cancer: A Propensity Score Analysis.
Jung SM; Yu CS; Park IJ; Kim TW; Kim JH; Yoon YS; Lim SB; Kim JC
Medicine (Baltimore); 2016 May; 95(20):e3718. PubMed ID: 27196490
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status.
Read TE; Andujar JE; Caushaj PF; Johnston DR; Dietz DW; Myerson RJ; Fleshman JW; Birnbaum EH; Mutch MG; Kodner IJ
Dis Colon Rectum; 2004 Jun; 47(6):825-31. PubMed ID: 15108025
[TBL] [Abstract][Full Text] [Related]
19. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
20. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial.
Hofheinz RD; Arnold D; Fokas E; Kaufmann M; Hothorn T; Folprecht G; Fietkau R; Hohenberger W; Ghadimi M; Liersch T; Grabenbauer GG; Sauer R; Rödel C; Graeven U;
Ann Oncol; 2018 Aug; 29(8):1793-1799. PubMed ID: 29873684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]